Stocktoria
Dianthus Therapeutics, Inc. /DE/ DNTH
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-06-21
Dianthus Therapeutics, Inc. /DE/ financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | — | — | — | $0 | $0 | $0 |
| R&D expense | $145.6M | $83.1M | $32.8M | $29.4M | $46.8M | $50.6M | $59.2M | $41.3M | $27.9M |
| Operating income | -$177.9M | -$101.9M | -$48.2M | -$29.7M | -$74.7M | -$78.7M | -$83.0M | -$60.0M | -$35.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$162.3M | -$85.0M | -$43.6M | -$28.5M | -$71.1M | -$74.9M | -$76.8M | -$57.5M | -$35.5M |
| EPS (diluted) | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-1.29 | $-1.71 | — | — | — |
| Operating cash flow | -$129.1M | -$78.2M | -$36.9M | -$29.1M | -$59.5M | -$64.0M | -$57.1M | -$41.9M | -$22.3M |
| Free cash flow | — | — | — | -$29.4M | -$60.8M | -$64.4M | -$60.2M | -$49.6M | -$24.5M |
| Cash & equivalents | $51.1M | $22.8M | $132.3M | $15.4M | $131.7M | $58.2M | $65.1M | $58.3M | $51.4M |
| Total assets | $530.9M | $374.0M | $179.4M | $83.1M | $189.9M | $161.6M | $161.5M | $157.3M | $54.5M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.5M | $17.3M | $17.7M | $20.3M | $11.7M | $4.1M |
| Shareholders' equity | $493.4M | $352.5M | $168.9M | -$44.4M | -$17.2M | $143.9M | $141.2M | $145.6M | -$42.1M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -67.3% | +120.6% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.